Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Ibrutinib and rituximab shows superior PFS vs. FCR in CLL

Jacqueline Barrientos • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Cyclophosphamide Fludarabine Ibrutinib Rituximab
ECOG-E1912

Jacqueline Barrientos, MD, Northwell Health, New York, NY, discusses the extended follow-up results from the E1912 trial (NCT02048813) comparing chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) to the combination of ibrutinib and rituximab (IR) for previously untreated chronic lymphocytic leukemia (CLL) patients. With extended follow-up, the combination of ibrutinib and rituximab continues to provide superior progression-free survival compared to FCR for younger patients with previously untreated CLL. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Jacqueline Barrientos

2:18
Advancements within the CLL treatment landscape
Jacqueline Barrientos • 13 Dec 2021
1:12
Novel treatment strategies for Richter’s transformation
Jacqueline Barrientos • 13 Dec 2021
2:37
Customizing CLL care with BTK Inhibitors
Jacqueline Barrientos • 13 Dec 2021
2:21
CAPTIVATE: Ibrutinib and venetoclax in CLL
Jacqueline Barrientos • 13 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals